CVRx, Inc. (CVRX)
CVRXNASDAQ-GSMedical/Dental Instruments
$0.6905
-0.0901 (-11.54%) today
Regular session, Nov 10, 1:57 PM ET
- Market cap
- $19.67m
- P/E
- –
- EPS, last 4 quarters
- $-2.01
- Dividend yield
- –
- Day range
- $0.6700 to $0.8200
- 52-week range
- $0.7200 to $10.28
- Average volume
- 751.2k
- Previous close
- $0.7806
Analysts
6 coveringHold2 buy, 4 hold, 0 sell
Targets a year out average $2.25, +225.9% from here
Earnings
next estimate $-0.5100Next report
Dec 2025
-9.5%
Mar 2026
+2.0%
Jun 2026
-1.9%
Sep 2026
-6.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $14.69m | $16.02m | $14.77m | $15.71m |
| Gross profit | $12.75m | $13.82m | $12.88m | $13.72m |
| Operating income | -$12.27m | -$11.18m | -$12.16m | -$13.02m |
| Net income | -$12.87m | -$11.93m | -$13.12m | -$14.04m |
Last four quarters: revenue $61.19m, margin -84.9%, free cash flow -$41.05m
News
8 latest- Friday's ETF Movers: PSI, RSSL BNK Invest · 4 days ago
- CVRx (CVRX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- CVRx Reports Q3 Revenue Decline; Lowers FY26 Outlook RTTNews · 4 days ago
- CVRx (CVRX) Reports Q3 Loss, Lags Revenue EstimatesZacks · 5 days ago
- Here's What Key Metrics Tell Us About CVRx (CVRX) Q3 EarningsZacks · 5 days ago
- CVRx Appoints As John Landry CFO RTTNews · Sep 21, 2026
- Beta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains?Zacks · Sep 17, 2026
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.The Motley Fool · Aug 31, 2026
The company
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- cvrx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.